The FDA posted on its website that Eli Lilly’s weight loss drug Zepbound has limited availability through the end of April due to demand increase for the drug.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Can Eli Lilly Stock Continue Its Bull Run? Here’s What Citi Expects
- Eli Lilly price target raised to $895 from $675 at Citi
- ResMed price target raised to $224 from $215 at Needham
- Lilly’s Zepbound in short supply at Amazon Pharmacy, Rite Aid, Bloomberg says
- Early notable gainers among liquid option names on March 28th
